Managing Idiopathic Hypersomnia and Narcolepsy from Diagnosis to Treatment in Community Settings

PRESENTING FACULTY

David T. Plante, MD, PhD Associate Professor of Psychiatry Medical Director, Wisconsin Institute for Sleep and Consciousness University of Wisconsin School of Medicine and Public Health Madison, Wisconsin

PROGRAM OVERVIEW

This interactive, expert-led ECHO series provides clinicians with practical tools on how to improve the timely and accurate identification and management of idiopathic hypersomnia (IH) and narcolepsy across diverse care settings. Participants will be able to implement best practices for differential diagnosis, including distinguishing IH from narcolepsy through targeted history, sleep testing, and guideline‑aligned evaluation. The program also explores the substantial disease burden, functional impairment, and common comorbidities that shape patient quality of life, emphasizing strategies to address them in routine care. Finally, learners will apply the latest clinical evidence to optimize treatment decisions, including considerations related to sodium intake when selecting and monitoring pharmacologic therapies.

TARGET AUDIENCE

This activity is designed to meet the educational needs of primary care physicians (PCPs), advanced care practitioners, sleep specialists, neurologists, cardiologists, nephrologists, and pulmonologists who provide care for patients with IH and narcolepsy.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Utilize best practices for differential diagnosis of IH and narcolepsy to facilitate prompt and accurate identification
• Recognize the disease burden and comorbidities of IH and narcolepsy that impact patient quality of life and how to address them
• Employ the latest clinical evidence for managing IH and narcolepsy to inform treatment decisions while considering sodium intake

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.

ACCME INNOVATION PARTNER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities that you specify.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, dietary, physical, etc). Please contact Med Learning Group prior to participating at [email protected]